From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival

Last Updated: Wednesday, February 15, 2023

A retrospective study of 354 patients who received alloHCT found that 71% of patients given initial systemic treatment for chronic GVHD were alive at one year with no recurrent malignancy or new systemic treatment. This could serve as a benchmark for resource-constrained locations.

Transplantation and Cellular Therapy
Advertisement
News & Literature Highlights
Advertisement
Advertisement